Edition:
United States

Dova Pharmaceuticals Inc (DOVA.OQ)

DOVA.OQ on NASDAQ Stock Exchange Global Market

34.68USD
16 Feb 2018
Change (% chg)

$0.78 (+2.30%)
Prev Close
$33.90
Open
$34.05
Day's High
$34.98
Day's Low
$31.30
Volume
50,235
Avg. Vol
33,080
52-wk High
$34.98
52-wk Low
$16.98

Chart for

About

Dova Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocyt... (more)

Overall

Beta: --
Market Cap(Mil.): $889.63
Shares Outstanding(Mil.): 25.65
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Dova Pharmaceuticals Reports Qtrly Loss Per Share $‍0.36​

* DOVA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING AND FINANCIAL RESULTS

Feb 15 2018

BRIEF-Dova Pharmaceuticals Announces Appointment Of Mark W. Hahn As Chief Financial Officer

* DOVA PHARMACEUTICALS ANNOUNCES THE APPOINTMENT OF MARK W. HAHN AS CHIEF FINANCIAL OFFICER

Jan 30 2018

BRIEF-Dova Pharmaceuticals Inc - Supplemental NDA For Avatrombopag in ITP To Be Submitted In Second Half Of 2018

* DOVA PHARMACEUTICALS PROVIDES UPDATE ON DEVELOPMENT STRATEGY FOR AVATROMBOPAG IN IMMUNE THROMBOCYTOPENIC PURPURA (ITP) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT)

Jan 03 2018

BRIEF-Dova Pharmaceuticals Announces FDA Acceptance Of The Avatrombopag New Drug Application With Priority Review

* DOVA PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF THE AVATROMBOPAG NEW DRUG APPLICATION (NDA) WITH PRIORITY REVIEW

Nov 27 2017

BRIEF-Dova Pharmaceuticals reports third quarter results

* Dova Pharmaceuticals reports third quarter 2017 operating and financial results

Nov 09 2017

BRIEF-Dova Pharmaceuticals announces New Drug Application submission to FDA

* Dova Pharmaceuticals announces New Drug Application submission to FDA for avatrombopag, a second generation thrombopoietin receptor agonist

Sep 22 2017

Earnings vs. Estimates